Abilify Tablet
Product Images NDC 59148-009

Product Visual Gallery

This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Abilify (NDC 59148-009). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Otsuka America Pharmaceutical, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Abilify 10 mg Tablets (Abilify 10mg Bottle Label)

Packaging label for ABILIFY (aripiprazole) tablets, 10 mg strength, oral dosage form. The label indicates a quantity of 30 tablets and includes directions to dispense with a medication guide. The labeler is Otsuka America Pharmaceutical, Inc. The label features the product name and strength prominently, with a barcode and regulatory information visible.*

FDA Label Image

Abilify 15 mg Tablets (Abilify 15mg Bottle Label)

ABIlIFY (aripiprazole) 15 mg tablets label from Otsuka America Pharmaceutical, Inc. The label indicates a package of 30 tablets for oral use, labeled for prescription use only with a directive to dispense with a medication guide. The National Drug Code (NDC) number shown is 59148-009-13.*

FDA Label Image

Abilify 20 mg Tablets (Abilify 20mg Bottle Label)

ABILIFY (aripiprazole) 20 mg oral tablets packaging label showing a box containing 30 tablets. The label includes the NDC number 59148-010-13, directs to dispense with medication guide, and is marked Rx only. The labeler is Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Ablify 2 mg Tablets (Abilify 2mg Bottle Label)

Label for ABILIFY (aripiprazole) 2 mg oral tablets, containing 30 tablets. The label shows the brand name ABILIFY prominently with the generic name aripiprazole underneath. It includes directions to dispense with medication guide and states prescription only (Rx only). The labeler is Otsuka America Pharmaceutical, Inc.*

FDA Label Image

Abilify 30 mg Tablets (Abilify 30mg Bottle Label)

Packaging label for ABILIFY (aripiprazole) 30 mg tablets by Otsuka America Pharmaceutical, Inc. The label indicates a 30-tablet count and prescription-only status. The design features the brand and generic names prominently, along with dosing strength and a barcode on the right side.*

FDA Label Image

Abilify 5 mg Tablets (Abilify 5mg Bottle Label)

ABILIFY 5 mg tablets packaging label for oral use by Otsuka America Pharmaceutical, Inc. The label shows the brand name, generic name aripiprazole, strength 5 mg, quantity of 30 tablets, and includes a note to dispense with medication guide. It also states prescription only (Rx only) and displays the NDC 59148-007-13.*

FDA Label Image

Chemical Structure (Abilify Chem Structure)

Chemical structure of aripiprazole showing its molecular framework including chlorinated aromatic ring, piperazine ring, and other connected groups.*

FDA Label Image

Figure 1 (Abilify Figure 01)

A pharmacokinetic chart showing the effect of various drugs on Abilify (aripiprazole) by depicting fold changes with 90% confidence intervals for AUC and Cmax relative to a reference without interacting drugs. The chart lists CYP3A4 and CYP2D6 inhibitors, CYP3A4 inducer, gastric acid blockers, and others like valproate, lithium, and lorazepam, illustrating their impact on aripiprazole exposure.*

FDA Label Image

Figure 2 (Abilify Figure 02)

Pharmacokinetic chart showing the effect of various drugs on the plasma concentrations (AUC and Cmax) of Abilify (aripiprazole). The graph presents fold changes and 90% confidence intervals for different inhibitors, inducers, gastric acid blockers, and other interacting drugs relative to a reference without interacting drugs.*

FDA Label Image

Figure 3 (Abilify Figure 03)

A pharmacokinetic chart titled 'Effect of Abilify on Other Drugs' showing fold changes with 90% confidence intervals for various drugs when co-administered with Abilify. The x-axis represents change relative to reference without interacting drug, ranging from 0.5 to 3.0. The y-axis lists drugs and enzymes like CYP2D6, CYP2C9, 2C19, UGT1A4, with PK parameters such as AUC, Cmax, INR, and DWDRP. Data points show observed effects on these other drugs' pharmacokinetics relative to control.*

FDA Label Image

Figure 4 (Abilify Figure 04)

This is a forest plot chart depicting the fold change and 90% confidence intervals of aripiprazole pharmacokinetics (AUC and Cmax) in various special populations. It compares poor vs. extensive metabolizers for CYP2D6, gender (female vs. male), age groups (18-64 vs. >65 years old), levels of hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment, showing changes in drug exposure relative to reference groups.*

FDA Label Image

Figure 5 (Abilify Figure 05)

A chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' displays fold changes in pharmacokinetics (AUC and Cmax) of dehydro-aripiprazole relative to reference across various factors including CYP2D6 metabolizer status, gender, age, hepatic impairment severity, and severe renal impairment. The x-axis shows change relative to reference from 0.5 to 3.0 with data points and confidence intervals for each factor condition.*

FDA Label Image

Figure 6 (Abilify Figure 06)

A Kaplan-Meier curve graph comparing the proportion of subjects experiencing relapse over 182 days from randomization between ABILIFY (aripiprazole) and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes numbers of subjects at risk for both groups over time.*

FDA Label Image

Figure 7 (Abilify Figure 07)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization, comparing ABILIFY (aripiprazole) and placebo groups. The chart includes numbers of subjects at risk at various time points for each group, illustrating relapse rates up to 182 days.*

FDA Label Image

Figure 8 (Abilify Figure 08)

A Kaplan-Meier curve chart comparing the proportion with relapse over 364 days from randomization for ABILIFY (aripiprazole) oral tablets versus placebo. The chart shows lower relapse rates over time with ABILIFY compared to placebo. The x-axis indicates days from randomization, and the y-axis shows the proportion with relapse. Below the graph, the number of subjects at risk at various time points for both ABILIFY and placebo groups is listed.*

FDA Label Image

Figure 9 (Abilify Figure 09)

A line graph showing the change in YGTSS total TIC score from baseline over 8 weeks of treatment. The graph compares three groups: ABILIFY low dose, ABILIFY high dose, and placebo, with scores decreasing over time, indicating differences in treatment effect.*

FDA Label Image

Abilify Injection For Intramuscular Use Only (PDP)

Packaging label for ABILIFY (aripiprazole) Injection 9.75 mg per 1.3 mL (7.5 mg/mL) by Otsuka America Pharmaceutical, Inc. The label indicates a single-use vial for intramuscular use only, with instructions to dispense with medication guide. The sterile, ready-to-use solution is prescription only, with storage and handling details visible on the label.*

FDA Label Image

Abilify 10-mg Orally Disintegrating Tablets (PDP)

ABIlIFY DISCMELT 10 mg (aripiprazole) orally disintegrating tablets label for 30 tablets (3 x 10) packaged by Otsuka America Pharmaceutical, Inc. The label includes the proprietary name, strength, generic name, dosage form, quantity, NDC 59148-640-23, and administration instruction to dispense with the medication guide.*

FDA Label Image

Abilify 15-mg Orally Disintegrating Tablets (PDP)

Packaging label for ABILIFY DISCMELT 15 mg (aripiprazole) orally disintegrating tablets by Otsuka America Pharmaceutical, Inc. The label indicates a supply of 30 tablets (3 tablets per 10 blister packs). The product is prescription only, with directions to dispense with the medication guide.*

FDA Label Image

Abilify Oral Solution 1mg/ml (PDP)

Packaging label for ABILIFY (aripiprazole) Oral Solution 1 mg/mL, 150 mL bottle. The label displays the brand and generic names, concentration, volume, and dosage form. It includes the National Drug Code (NDC 59148-013-15), directions to dispense with medication guide, and manufacturer information for Otsuka America Pharmaceutical, Inc. The label also contains storage instructions and regulatory markings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.